Rubinstein, Maria M <br/><br/>
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.  [electronic resource] 

 -  Cancer  03 2020 
 - 1274-1282 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.32677  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Class I Phosphatidylinositol 3-Kinases<br/>Class Ia Phosphatidylinositol 3-Kinase--genetics<br/>Endometrial Neoplasms--drug therapy<br/>Enzyme Activation<br/>Female<br/>Humans<br/>Hyperglycemia--chemically induced<br/>Hypoalbuminemia--chemically induced<br/>Hypophosphatemia--chemically induced<br/>Middle Aged<br/>Mutation<br/>PTEN Phosphohydrolase--genetics<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Progression-Free Survival<br/>Proto-Oncogene Proteins c-akt--genetics<br/>Pyridines--adverse effects<br/>Quinolones--adverse effects<br/>Signal Transduction<br/>TOR Serine-Threonine Kinases<br/>Treatment Outcome